Show overview
Prostate Cancer Update has been publishing since 2022, and across the 4 years since has built a catalogue of 66 episodes. That works out to roughly 65 hours of audio in total. Releases follow a monthly cadence, with the show now in its 24th season.
Episodes typically run thirty-five to sixty minutes — most land between 45 min and 1h 4m — though episode length varies meaningfully from one episode to the next. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language Science show.
The show is actively publishing — the most recent episode landed 5 days ago, with 19 episodes already out so far this year. The busiest year was 2026, with 19 episodes published. Published by Dr. Neil Love.
From the publisher
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing urologists and radiation oncologists ongoing access to the perspectives and opinions of national and international prostate cancer research leaders.
Latest Episodes
View all 66 episodesUrothelial Bladder Cancer — Year in Review Series on Relevant New Datasets and Advances
Prostate Cancer — Fifth Annual National General Medical Oncology Summit
Urothelial Bladder Cancer — Fifth Annual National General Medical Oncology Summit
Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting
Localized Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting
Genitourinary Cancers — 5-Minute Journal Club Issue 2 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Genitourinary Cancers — 5-Minute Journal Club Issue 1 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida
Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances
Metastatic Bladder Cancer — Rapid Case Review Issue 4
S24 Ep 36AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Prof Karim Fizazi from the Centre Oscar Lambret in Lille, France, Dr Daniel George from the Duke Cancer Institute in Durham, North Carolina, and moderator Dr Elisabeth I Heath from Mayo Clinic in Rochester, Minnesota, discuss the future role of AKT inhibition in prostate cancer.CME information and select publications here.
S24 Ep 35Metastatic Bladder Cancer — Rapid Case Review Issue 3
Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston. CME information and select publications here.
S24 Ep 34Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Dr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Dr Shilpa Gupta from Cleveland Clinic’s Taussig Cancer Institute in Ohio, Prof Andrea Necchi from IRCCS San Raffaele Hospital in Milan, Italy, and moderator Dr Terence Friedlander from the University of California, San Francisco discuss recent data surrounding the management of non-muscle-invasive and muscle-invasive bladder cancer, alongside their perspectives on clinical application and disease management.CME information and select publications here.
S24 Ep 33Urothelial Bladder Cancer — Microlearning Activity 2 with Dr Terence Friedlander: ESMO Congress 2025 Review
Dr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress.CME information and select publications here.
S24 Ep 32Metastatic Bladder Cancer — Rapid Case Review Issue 2
Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York.CME information and select publications here.
S24 Ep 31Prostate Cancer — Microlearning Activity 2 with Dr Rana R McKay: ESMO Congress 2025 Review
Dr McKay discusses the selection of and efficacy data with androgen pathway-targeting agents for patients with prostate cancer and reviews recently presented clinical findings from the ESMO Congress 2025.CME information and select publications here.
S24 Ep 30Urothelial Bladder Cancer — Microlearning Activity 1 with Dr Terence Friedlander: ESMO Congress 2025 Review
Dr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress.CME information and select publications here.
S24 Ep 29Prostate Cancer — Microlearning Activity 1 with Dr Rana R McKay: ESMO Congress 2025 Review
Dr Rana R McKay discusses the selection and sequencing of therapy for patients with prostate cancer in a review of recently presented clinical findings from ESMO Congress 2025.CME information and select publications here.
S24 Ep 28Metastatic Bladder Cancer — Rapid Case Review Issue 1
Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York.CME information and select publications here.
S24 Ep 27Urothelial Bladder Cancer and Prostate Cancer — Highlights from the 2025 ESMO Annual Meeting
Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center and Dr Rana R McKay from the UC San Diego Moores Cancer Center summarize the treatment landscape for prostate and urothelial bladder cancer and discuss the implications of clinical findings recently presented at the ESMO Congress 2025.CME information and select publications here.